Skip to search formSkip to main contentSkip to account menu

PF 04217329

Known as: PF-04217329, PF04217329 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

AcetatesSulfonamides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Investigation of Corneal Effects of Taprenepag Isopropyl (PF-04217329) by Confocal Microscopy
2011
2011
Pharmacodynamic Modeling of 24-Hour Intraocular Pressure Lowering for Taprenepag Isopropyl (PF-04217329), a Selective EP2 Receptor Agonist, as Monotherapy and in Combination with Latanaprost
2011
2011
Nonclinical Assessment of the Effect of Taprenepag Isopropyl (PF-04217329) Formulated With and Without Benzylkonium Chloride (BAC) and Xalatan® on Intraocular Exposure of the Active Metabolites of…
2010
2010
Dose-Escalating, Double-Masked, Vehicle-Controlled Trial of the IOP-Reducing Effect of the EP2 Agonist PF-04217329
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)